Key result
IV exposure to reformulated ER oxymorphone inert ingredients linked to thrombotic microangiopathy.
Why the study?
Thrombotic microangiopathy has been reported following IV abuse of extended-release oxymorphone tablets, but the causal mechanism involving inert ingredients was unclear.
Does IV exposure to the inert ingredients of extended-release oxymorphone cause thrombotic microangiopathy?
Population
3 patients with recent injection of adulterated extended-release oxymorphone tablets and guinea pig animal model
Comparison
IV exposure to inert ingredient mixture (PEO+) vs no exposure
Design
Case report with animal model investigation
Authors
Loading...
May prompt TMA evaluation in oxymorphone abusers; hypothesis-generating for excipient toxicity and needs validation.
Case Report (n=3)
Does IV exposure to the inert ingredients of extended-release oxymorphone cause thrombotic microangiopathy?
IV abuse of extended-release oxymorphone can cause thrombotic microangiopathy due to exposure to its inert high-molecular-weight polyethylene oxide ingredients.
Hunt et al. (2016) conducted a case report in Thrombotic microangiopathy (n=3). IV abuse of extended-release oxymorphone hydrochloride (Opana ER) was evaluated on Development of thrombotic microangiopathy. IV exposure to the inert ingredients in reformulated extended-release oxymorphone elicited thrombotic microangiopathy in 3 patients and a guinea pig model.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: